Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Oct 02, 2021 7:33am
170 Views
Post# 33957147

RE:CEO bought 100k - just filed

RE:CEO bought 100k - just filedI think the insider buy is more of a strategic nature than a minor addition to the millions of shares that he already owns for growing wealth.

According to the last NR there was meetings scheduled with the top-10 pharma company with the sole purpose to nail a deal. So when the CEO bought his 100K the negotiation meetings had begun.

Pure speculation, but I think that SBM has put forward pretty aggressive terms and the top-10 pharma tries to get away cheap. The negitiation can take a long time and it's important that SBM does not starve to death in the process. The warrants due mid October are key. Bottom line, I think the CEO is trying to support the share price in order to encourage the warrant holders to exercise.
<< Previous
Bullboard Posts
Next >>